Nordmark Arzneimittel GmbH & Co. KG
25436 Uetersen, Schleswig-Holstein
Jan Heyland, Head of Biotech Development
Company main phone:
+49 (4122) 7120 Company main fax:
+49 (4122) 712220 Website: www.nordmark-pharma.de
|Source of foundation:||Management buy-out (MBO)|
|Name of foundation source:||BASF Group|
|No. of employees:
Corporate description / mission:
Nordmark are specialists in the manufacture of active pharmaceutical ingredients and drug products of biological origin. The pharmaceutical products in Nordmark’s product portfolio contain active ingredients produced in-house, such as pancreatin, heparin and Pepsin Ph. Eur.
The company's work is aimed at continuously optimising existing production processes and developing innovative biological active pharmaceutical ingredients and drug products. In doing so, they service the full process range, from extraction, fermentation, purification and characterisation of proteins, via the development of the required analytical procedures, all the way to establishing GMP compliant manufacturing processes and the performance of ICH compliant stability studies, method validations and formulation of the finished pharmaceutical product.
State of ownership: Private / independent
- Biotechnology - R&D Services
- Analytical services
- Cell culture
- CMO (Contract Manufacturing Organization)
- Service company
- Supplier / Distributor
- Large biotech & big pharma
- Small biotech
Summary Products / Services / Technologies
Description of products:
Pancreatin pellets, etc.
Development/optimisation of strains or cell cultures
Development of the formulation
Manufacture of clinical samples
Support in clinical trials and regulatory discussions.